Novel targeted therapies for R/R CLL, including venetoclax plus rituximab, acalabrutinib, and zanubrutinib, have favorable safety profiles. Bendamustine plus rituximab showed a lower risk of severe ...

Sofi-cel, an allogeneic CAR-T therapy, targets CD7 and uses CRISPR/Cas9 to prevent fratricide and reduce graft-versus-host disease risk. The FDA's breakthrough therapy designation facilitates ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved revumenib for patients aged 1 year and older with relapsed or refractory acute myeloid leukemia ...

ORLANDO, Fla. — Adding epcoritamab (Epkinly) to the standard-of-care (SOC) therapy of lenalidomide (Revlimid) and rituximab (Rituxan), a combination known as R 2, lowered the risk for disease ...

When it comes to relapsed/refractory follicular lymphoma, chimeric antigen receptor (CAR) T-cell therapy has become a go-to treatment for some patients, with its high end durable response rates, and ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved ziftomenib for adult patients with relapsed or refractory acute myeloid leukemia with a ...

The objective response rate was 70%, with 45% of patients achieving a complete response or better. The Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic ™ (linvoseltamab ...

During a live event, Patrick Hagen, MD, considered the evidence for using teclistamab plus daratumumab in a patient with myeloma relapse after quadruplet induction and transplant.

Real world outcomes of venetoclax combined with hypomethylating agents in acute myeloid leukemia and myelodysplastic syndrome: Insights from a tertiary care centre in Pakistan. This is an ASCO Meeting ...

Monjuvi in combination with lenalidomide and rituximab significantly improved PFS in patients with relapsed/refractory follicular lymphoma. The Food and Drug Administration (FDA) has approved Monjuvi ...

Good day, everyone, and welcome to the Syndax Conference Call to Discuss the FDA approval of Revuforj in Relapsed/Refractory NPM1 Mutated AML. Today's call is being recorded. [Operator Instructions] ...